Dear Healthcare Provider,
The information contained here may be very important to your practice. Please take a moment to review this document.
DRUG SCREEN PANEL UPDATES
Alverno Laboratories is pleased to announce an update to and consolidation of our Drug of Abuse screening panels. The new panels will be offered with or without confirmation. All previous panels will be discontinued except for the Occupational Medicine drug screen panels and drug screen panels performed at the local hospital sites. Please see page 2 through 4 for details.
LUPUS ANTICOAGULANT AND ANTI-PHOSPHOLIPID SYNDROME PANELS
February 4, 2020
Effective February 4, 2020, Alverno will resume Lupus Anticoagulant Reflexive Panel testing in-house and offer an additional Anti-Phospholipid Syndrome Panel. Please see page 5 for details.
PAIN MANAGEMENT PANEL UPDATE
February 18, 2020
Alverno Laboratories is pleased to announce Pain Management Panel testing will now be conducted in-house on our Liquid Chromatography Mass Spectrometer (LCMS), reducing turnaround time. Alverno’s Pain Management Panel will be more comprehensive, consisting of 79 reported analytes, specimen validity, and an interpretation based on the submitted medication list. Please see page 6 through 9 for details.